{"id":"caelyx","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02626455","NCT00003380","NCT00303108","NCT01940497","NCT00525759","NCT00949325","NCT04457089","NCT00002791","NCT01985724","NCT01848652","NCT06652152","NCT06470633","NCT05054478","NCT07424287","NCT03226249","NCT00005830","NCT00006034","NCT00895414","NCT00554164","NCT04258163","NCT00003084","NCT00135499","NCT00992706","NCT01670084","NCT03017404","NCT00742404","NCT05483933","NCT05315336","NCT05040906","NCT02789332","NCT04956068","NCT00877006","NCT00097981","NCT00052065","NCT00795899","NCT01852799","NCT04138719","NCT02372409","NCT00011414","NCT00002526","NCT00191789","NCT00080782","NCT00913835","NCT06526923","NCT05020860","NCT02903524","NCT00577096","NCT06468943","NCT00931918","NCT01502982"],"aliases":["liposomal doxorubicin","Caelyx"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Caelyx","companyId":"ludwig-institute-for-cancer-research","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Ludwig Institute for Cancer Research","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Caelyx","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02626455","phase":"Phase 3","title":"A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patie","status":"TERMINATED","sponsor":"Bayer","isPivotal":true,"enrollment":551,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2023-11-10"},{"nctId":"NCT00003380","phase":"Phase 1","title":"A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","isPivotal":false,"enrollment":0,"indication":"Fallopian Tube Cancer, Ovarian Cancer","completionDate":""},{"nctId":"NCT00303108","phase":"Phase 2","title":"Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"US Oncology Research","isPivotal":false,"enrollment":136,"indication":"Metastatic Breast Cancer","completionDate":"2011-06"},{"nctId":"NCT01940497","phase":"Phase 3","title":"National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":240,"indication":"Breast Cancer","completionDate":"2018-03-27"},{"nctId":"NCT00525759","phase":"Phase 2","title":"A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","isPivotal":false,"enrollment":40,"indication":"Breast Cancer","completionDate":"2010-01"},{"nctId":"NCT00949325","phase":"Phase 1","title":"Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":24,"indication":"Sarcoma","completionDate":"2012-09"},{"nctId":"NCT04457089","phase":"EARLY/Phase 1","title":"Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer","status":"COMPLETED","sponsor":"Marc Goodman","isPivotal":false,"enrollment":18,"indication":"Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer","completionDate":"2025-05-12"},{"nctId":"NCT00002791","phase":"Phase 2","title":"A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","isPivotal":false,"enrollment":0,"indication":"Sarcoma","completionDate":"2013-11"},{"nctId":"NCT01985724","phase":"Phase 3","title":"A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in ","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","isPivotal":true,"enrollment":650,"indication":"Breast Cancer","completionDate":"2013-12"},{"nctId":"NCT01848652","phase":"Phase 2","title":"Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Ch","status":"TERMINATED","sponsor":"University Hospital, Brest","isPivotal":false,"enrollment":5,"indication":"Cerebral Lymphoma B Cell Refractory","completionDate":"2015-05"},{"nctId":"NCT06652152","phase":"N/A","title":"Mechanism Investigation of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double ","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","isPivotal":false,"enrollment":400,"indication":"Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma","completionDate":"2025-12-30"},{"nctId":"NCT06470633","phase":"Phase 2","title":"To Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy Neoadjuvant Therapy in Early or Local Advanced Breast Cancer After Induction Treatment of High-intensity Focused Ultrasoun","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","isPivotal":false,"enrollment":29,"indication":"Breast Cancer, HR+/HER2- Breast Cancer","completionDate":"2026-12-31"},{"nctId":"NCT05054478","phase":"Phase 2","title":"Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation : PCL-2 Study","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":29,"indication":"Plasma Cell Leukemia","completionDate":"2028-02"},{"nctId":"NCT07424287","phase":"Phase 3","title":"A Multicenter, Randomized, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unre","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","isPivotal":true,"enrollment":236,"indication":"NMIBC","completionDate":"2030-06"},{"nctId":"NCT03226249","phase":"Phase 2","title":"Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","isPivotal":false,"enrollment":30,"indication":"Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma","completionDate":"2024-10"},{"nctId":"NCT00005830","phase":"Phase 1","title":"Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","isPivotal":false,"enrollment":31,"indication":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma","completionDate":""},{"nctId":"NCT00006034","phase":"Phase 3","title":"A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Re","status":"COMPLETED","sponsor":"Intracel","isPivotal":true,"enrollment":0,"indication":"Bladder Cancer","completionDate":"2004-03"},{"nctId":"NCT00895414","phase":"NA","title":"The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":19,"indication":"Breast Cancer","completionDate":"2015-10"},{"nctId":"NCT00554164","phase":"Phase 3","title":"Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"University Hospital, Essen","isPivotal":true,"enrollment":1073,"indication":"Lymphoma, High-grade","completionDate":"2017-03"},{"nctId":"NCT04258163","phase":"N/A","title":"Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","isPivotal":false,"enrollment":760,"indication":"Metastatic Breast Cancer","completionDate":"2019-07-01"},{"nctId":"NCT00003084","phase":"Phase 2","title":"A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":75,"indication":"Prostate Cancer","completionDate":"2002-11"},{"nctId":"NCT00135499","phase":"Phase 3","title":"Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Lymphoma Study Association","isPivotal":true,"enrollment":138,"indication":"Lymphoma, Large-Cell, Diffuse","completionDate":"2010-04-27"},{"nctId":"NCT00992706","phase":"Phase 3","title":"Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":true,"enrollment":91,"indication":"Breast Cancer, Palmar-plantar Erythrodysesthesia","completionDate":"2012-06"},{"nctId":"NCT01670084","phase":"Phase 2","title":"A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid","status":"WITHDRAWN","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":0,"indication":"B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia","completionDate":"2017-09"},{"nctId":"NCT03017404","phase":"NA","title":"A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection in Neoadjuvant Chemotherapy for Patients With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","isPivotal":false,"enrollment":18,"indication":"Breast Cancer","completionDate":"2016-07"},{"nctId":"NCT00742404","phase":"Phase 2","title":"A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Oncotherapeutics","isPivotal":false,"enrollment":35,"indication":"Multiple Myeloma and Plasma Cell Neoplasm","completionDate":""},{"nctId":"NCT05483933","phase":"Phase 1","title":"An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers","status":"COMPLETED","sponsor":"Shattuck Labs, Inc.","isPivotal":false,"enrollment":86,"indication":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2025-02-07"},{"nctId":"NCT05315336","phase":"Phase 3","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV Associated Hemophagocytic Lymphohistiocytosis (HLH)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","isPivotal":true,"enrollment":50,"indication":"Hemophagocytic Lymphohistiocytosis","completionDate":"2026-06-01"},{"nctId":"NCT05040906","phase":"Phase 3","title":"A Phase 3, Randomized, Double-blind Study of H02 Plus CHOP Versus R-CHOP in Patients With Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","isPivotal":true,"enrollment":416,"indication":"Recruiting","completionDate":"2023-12-31"},{"nctId":"NCT02789332","phase":"Phase 2","title":"A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients ","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","isPivotal":false,"enrollment":107,"indication":"Breast Cancer, Triple Negative Breast Neoplasms","completionDate":"2020-02"},{"nctId":"NCT04956068","phase":"Phase 1","title":"Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","isPivotal":false,"enrollment":25,"indication":"Peritoneal Metastases","completionDate":"2024-11"},{"nctId":"NCT00877006","phase":"Phase 3","title":"An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosp","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","isPivotal":true,"enrollment":447,"indication":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","completionDate":"2012-03-31"},{"nctId":"NCT00097981","phase":"Phase 3","title":"A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Mult","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":225,"indication":"Multiple Myeloma","completionDate":"2009-10"},{"nctId":"NCT00052065","phase":"Phase 1","title":"Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Telik","isPivotal":false,"enrollment":28,"indication":"Ovarian Neoplasms","completionDate":"2006-03"},{"nctId":"NCT00795899","phase":"Phase 2","title":"Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","isPivotal":false,"enrollment":230,"indication":"Breast Cancer","completionDate":"2008-09"},{"nctId":"NCT01852799","phase":"Phase 2","title":"A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed","status":"COMPLETED","sponsor":"Shanghai Changzheng Hospital","isPivotal":false,"enrollment":18,"indication":"Multiple Myeloma","completionDate":"2017-01"},{"nctId":"NCT04138719","phase":"Phase 2","title":"Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","isPivotal":false,"enrollment":520,"indication":"Breast Cancer, Triple-negative Breast Cancer","completionDate":"2028-06-20"},{"nctId":"NCT02372409","phase":"Phase 2","title":"A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors","status":"TERMINATED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":6,"indication":"Glioma, Pilocytic Astrocytoma","completionDate":"2023-03-23"},{"nctId":"NCT00011414","phase":"Phase 1","title":"Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":29,"indication":"Wilms' Tumor, Sarcoma","completionDate":"2016-01-13"},{"nctId":"NCT00002526","phase":"Phase 2","title":"Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":20,"indication":"Ovarian Cancer, Sarcoma","completionDate":"1995-09"},{"nctId":"NCT00191789","phase":"Phase 2","title":"Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":65,"indication":"Breast Cancer","completionDate":"2009-04"},{"nctId":"NCT00080782","phase":"Phase 2","title":"A Randomized Phase II Trial of Bone-Targeted Therapy Consisting of Strontium-89 and Doxorubicin With or Without Celecoxib in Androgen-Independent Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":14,"indication":"Metastatic Cancer, Prostate Cancer","completionDate":"2005-01"},{"nctId":"NCT00913835","phase":"Phase 2","title":"Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractor","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":125,"indication":"Ovarian Neoplasms","completionDate":"2014-02"},{"nctId":"NCT06526923","phase":"Phase 1","title":"A Single Ascending Dose, Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SP-101 Via Nebulizer for the Treatment of Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Spirovant Sciences, Inc.","isPivotal":false,"enrollment":15,"indication":"Cystic Fibrosis","completionDate":"2026-12-31"},{"nctId":"NCT05020860","phase":"Phase 2","title":"A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Baylor Breast Care Center","isPivotal":false,"enrollment":185,"indication":"Breast Cancer, Breast Neoplasm","completionDate":"2029-11"},{"nctId":"NCT02903524","phase":"Phase 4","title":"The Efficacy and Safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cance","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","isPivotal":false,"enrollment":300,"indication":"Breast Cancer","completionDate":"2018-12"},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","isPivotal":false,"enrollment":120,"indication":"Multiple Myeloma","completionDate":"2004-06"},{"nctId":"NCT06468943","phase":"Phase 2","title":"Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients in Treatment of Newly Diagnosed Untreated Non-GCB DLBCL With Extranodal Involvement.","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":20,"indication":"Effects of Chemotherapy, Safety Issues","completionDate":"2028-05-01"},{"nctId":"NCT00931918","phase":"Phase 2","title":"An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","isPivotal":false,"enrollment":206,"indication":"Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)","completionDate":"2015-08"},{"nctId":"NCT01502982","phase":"Phase 2","title":"CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase","status":"COMPLETED","sponsor":"Nordic Lymphoma Group","isPivotal":false,"enrollment":160,"indication":"Diffuse Large B-Cell Lymphoma","completionDate":"2014-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}